Warburg Pincus group to buy control of Pantherx Rare

A Warburg Pincus-led investor group has agreed to acquire a controlling stake in Pantherx Rare, a US-based pharmacy, PE Hub reported. Financial terms of the transaction were not disclosed.

The deal would shift control of Pantherx Rare to the Warburg Pincus-led group while leaving existing investors with continued exposure to the company. PE Hub reported that Nautic Partners and Pantherx management will remain significant shareholders following the transaction.

A controlling stake generally gives the buyer effective authority over major corporate decisions, depending on the final governance arrangements and shareholder agreements. In private equity transactions, sellers or management teams often retain minority holdings to participate in future value creation and align incentives after a change in control.

Pantherx Rare is led by chief executive Bansi Nagji, according to PE Hub. The company was founded in Pittsburgh in 2011, initially operating from a garage, PE Hub reported.

The reported transaction adds to private equity activity in healthcare services, where investors have continued to pursue businesses tied to specialty care and pharmacy operations. PE Hub did not report a valuation, closing timetable, financing structure or other members of the investor group.

This story draws on original reporting from PE Hub.